KIT Mutations in AML by Fragment Analysis and Sequencing
Prognostication in core-binding factor-related (CBF) AML.
New York DOH Approval Status
Lavender (EDTA) or green (Sodium heparin) whole blood or bone marrow.
Whole Blood: Do not freeze. Transport 5 mL whole blood. (Min: 1 mL)
Bone Marrow: Do not freeze. Transport 3 mL bone marrow (Min: 1 mL).
Plasma, serum, FFPE tissue blocks/slides, or frozen tissue. Specimens collected in anticoagulants other than EDTA or sodium heparin. Clotted or grossly hemolyzed specimens.
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2002439||Kit Mutations in AML||55201-8|
- CBF AML testing
- Exon 8 and 17
- KIT ex 8
- KIT exon 8